Compass Therapeutics Inc. (CMPX)
CMPX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.8570
-8.59% on the day
Market cap
$154.3M
Micro cap
Revenue · 2025
$0
No prior year to compare
Net income · 2025
-$66.5M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/0001171843-26-001337-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CMPX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001738021 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$66.5M |
| Operating income | -$72.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $30.6M |
| Total assets | $219.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-12-30 |
| Latest annual report FORM 10-K | 10-K | 2026-03-05 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-06 |
| Latest current report FORM 8-K | 8-K | 2026-09-22 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 359 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| IPHA | Innate Pharma S.A. ADS | $1.47 | -0.68% | $164.2M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $1.20 | +1.70% | $144.8M |
| CHRS | Coherus Oncology Inc. | $1.07 | +3.88% | $165.3M |
| DTIL | Precision BioSciences Inc. | $6.10 | -6.58% | $168.4M |
| MOLN | Molecular Partners AG | $3.67 | -3.17% | $137.7M |
| OTLK | Outlook Therapeutics Inc. | $0.5638 | -3.64% | $137.3M |
| AVXL | Anavex Life Sciences Corp. | $1.48 | -1.99% | $137.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier